Jasper Therapeutics (JSPR, Financial) has been downgraded by Cantor Fitzgerald in a recent analyst update. The rating for JSPR was adjusted from "Overweight" to "Neutral" by analyst Pete Stavropoulos.
This rating change reflects a shift in analyst sentiment towards Jasper Therapeutics' market performance. As of now, no adjustments have been made to the target price for JSPR, and figures regarding current or previous price targets have not been disclosed.
The downgrade was officially recorded on July 7, 2025, emphasizing Cantor Fitzgerald's re-evaluation of Jasper Therapeutics' position in the market. Investors are advised to note this latest update as part of their strategic decision-making processes regarding JSPR investments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 1,474.84% from the current price of $3.04. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
